Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7

By Daemen T.   Riezebos-Brilman A.   Bungener L.   Regts J.   Dontje B.   Wilschut J.  

Vaccine, Vol. 21, Iss. 11, 2003-03 ,pp. : 1082-1088

Elsevier

Access to resources Recommend Favorite

Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines

By Chen C.-H.   Wang T.-L.   Hung C.-F.   Pardoll D.M.   Wu T.-C.  

Vaccine, Vol. 18, Iss. 19, 2000-04 ,pp. : 2015-2022

Elsevier

Access to resources Recommend Favorite

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

By Cassetti M.C.   McElhiney S.P.   Shahabi V.   Pullen J.K.   Le Poole I.C.   Eiben G.L.   Smith L.R.   Kast W.M.  

Vaccine, Vol. 22, Iss. 3, 2004-01 ,pp. : 520-527

Elsevier

Access to resources Recommend Favorite

Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine

By de Jong A.   O'Neill T.   Khan A.Y.   Kwappenberg K.M.C.   Chisholm S.E.   Whittle N.R.   Dobson J.A.   Jack L.C.   St Clair Roberts J.   Offringa R.   van der Burg S.H.   Hickling J.K.  

Vaccine, Vol. 20, Iss. 29, 2002-10 ,pp. : 3456-3464

Elsevier

Access to resources Recommend Favorite

Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design

By Herrera O.B.   Brett S.   Lechler R.I.  

Vaccine, Vol. 21, Iss. 3, 2002-12 ,pp. : 231-242

Elsevier

Access to resources Recommend Favorite